 SAN CARLOS, Calif., Oct. 23, 2022 GLOBE NEWSWIRE -- Vaxcyte, Inc. Nasdaq: PCVX, a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to provide topline results from its Phase 12 proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Companys investigational 24-valent pneumococcal conjugate vaccine PCV, in healthy adults aged 18-64. 